Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
120 participants
OBSERVATIONAL
2016-09-06
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Proton MR Spectroscopy and 18F-Fluorocholine PET for Breast Cancer Diagnosis
NCT01956409
Early Interim 18F-FDG-PET and 18F-FLT-PET for Predicting Treatment Response and Survival in Metastatic Breast Cancer
NCT04411966
Whole-Body 18F-FDG PET in Induction Chemotherapeutic Response for Advanced NPC Patients
NCT00304694
Comparing 18F-FAPI-04 and 18F-FDG PET/CT in Cancer Detection
NCT06206642
Comaprison of 68Ga-FAP-2286 and 18F-FDG PET/CT in Patients With Various Types of Cancer
NCT05392205
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Age ≥ 20 years old.
2. Confirmed diagnosis of primary cancer of the following: NSCLC, breast or abdominal cancers
3. ECOG performance status 0 to 2.
4. Life expectancy \> 3 months.
5. Consent to perform additional 18F-FSPG and 18F-FDG PET prior to therapy.
6. Sexually active subjects agree to use condoms and/or their partners of reproductive potential to use a method of effective birth control during imaging period of 2 weeks.
Exclusion Criteria
1. Had received previous treatment (excluding neoadjuvant therapy).
2. Pregnant or lactating women.
3. Known malignancy in other organs.
4. Evaluated by primary care physician as unsuitable.
5. Known hypersensitivity to the study drug.
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Taiwan University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mei-Fang Cheng, MD
Role: PRINCIPAL_INVESTIGATOR
National Taiwan University Hospital Department of Nuclear Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Taiwan University Hospital
Taipei, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
201412135MINC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.